X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PIRAMAL ENTERPRISES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PIRAMAL ENTERPRISES CIPLA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 44.7 37.9 117.8% View Chart
P/BV x 3.7 3.8 97.5% View Chart
Dividend Yield % 0.3 0.6 54.2%  

Financials

 CIPLA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    CIPLA
Mar-17
PIRAMAL ENTERPRISES
Mar-16
CIPLA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6221,065 58.4%   
Low Rs458805 56.9%   
Sales per share (Unadj.) Rs181.9383.0 47.5%  
Earnings per share (Unadj.) Rs12.955.1 23.4%  
Cash flow per share (Unadj.) Rs29.374.1 39.6%  
Dividends per share (Unadj.) Rs2.0017.50 11.4%  
Dividend yield (eoy) %0.41.9 19.8%  
Book value per share (Unadj.) Rs155.7719.9 21.6%  
Shares outstanding (eoy) m804.51172.56 466.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.4 121.7%   
Avg P/E ratio x42.017.0 247.2%  
P/CF ratio (eoy) x18.412.6 145.9%  
Price / Book Value ratio x3.51.3 267.1%  
Dividend payout %15.531.8 48.9%   
Avg Mkt Cap Rs m434,516161,344 269.3%   
No. of employees `00023.03.8 609.1%   
Total wages/salary Rs m26,33816,898 155.9%   
Avg. sales/employee Rs Th6,349.117,472.6 36.3%   
Avg. wages/employee Rs Th1,143.04,466.9 25.6%   
Avg. net profit/employee Rs Th449.32,512.8 17.9%   
INCOME DATA
Net Sales Rs m146,30266,099 221.3%  
Other income Rs m2,2872,425 94.3%   
Total revenues Rs m148,58968,524 216.8%   
Gross profit Rs m24,75818,723 132.2%  
Depreciation Rs m13,2293,274 404.0%   
Interest Rs m1,5949,388 17.0%   
Profit before tax Rs m12,2228,485 144.0%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m-701,593 -4.4%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,7981,032 174.2%   
Profit after tax Rs m10,3549,506 108.9%  
Gross profit margin %16.928.3 59.7%  
Effective tax rate %14.712.2 120.9%   
Net profit margin %7.114.4 49.2%  
BALANCE SHEET DATA
Current assets Rs m87,37047,488 184.0%   
Current liabilities Rs m33,081104,362 31.7%   
Net working cap to sales %37.1-86.0 -43.1%  
Current ratio x2.60.5 580.4%  
Inventory Days Days8741 214.1%  
Debtors Days Days6251 121.8%  
Net fixed assets Rs m111,56726,532 420.5%   
Share capital Rs m1,609345 466.2%   
"Free" reserves Rs m123,645114,024 108.4%   
Net worth Rs m125,254124,221 100.8%   
Long term debt Rs m36,45475,812 48.1%   
Total assets Rs m209,532308,356 68.0%  
Interest coverage x8.71.9 455.3%   
Debt to equity ratio x0.30.6 47.7%  
Sales to assets ratio x0.70.2 325.7%   
Return on assets %5.76.1 93.1%  
Return on equity %8.37.7 108.0%  
Return on capital %8.510.0 85.3%  
Exports to sales %34.217.2 199.0%   
Imports to sales %8.36.6 126.3%   
Exports (fob) Rs m50,05011,362 440.5%   
Imports (cif) Rs m12,2034,364 279.6%   
Fx inflow Rs m51,06614,435 353.8%   
Fx outflow Rs m17,6785,183 341.1%   
Net fx Rs m33,3889,253 360.8%   
CASH FLOW
From Operations Rs m23,824-67,773 -35.2%  
From Investments Rs m-13,127-8,768 149.7%  
From Financial Activity Rs m-13,23976,199 -17.4%  
Net Cashflow Rs m-2,478-342 723.7%  

Share Holding

Indian Promoters % 16.0 52.9 30.2%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.0 305.0%  
FIIs % 23.7 26.6 89.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 16.5 158.8%  
Shareholders   161,166 93,274 172.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 17, 2017 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS